Learn More
4532 Background: The EGFR inhibitor, erlotinib (E), in combination with gemcitabine (G), provides a significant survival benefit in metastatic pancreatic cancer. Rash, a common toxicity with EGFR(More)
OBJECTIVE To evaluate the accuracy of fine needle aspiration cytology (FNAC) in BI-RADS3 breast lesions. METHODS Between January 2004 and December 2007, 337 cases from BI-RADS3 lesions underwent(More)
  • 1